Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Virbac SA

Virbac offers veterinarians, farmers and pet owners in more than 100 countries a comprehensive and practical range of products and services focused on animal health, self-described as providing innovative solutions covering the majority of animal species and diseases.

msh id	COM:VIRBAC:CORPORATE
symbol	VIRP
name	Virbac SA
homepage url	https://corporate.virbac.com
country	FR
sector	Healthcare
industry	Drug Manufacturers - General
market	STOCKS
employee count	5.46K
crunchbase url	-
linkedin url	-
founders	-

market cap	3.12B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-1
growth cost of revenue	-1
growth depreciation and amortization	-1
growth ebitda	4.69
growth ebitda ratio	4.55
growth eps	-1
growth eps diluted	-1
growth general and administrative expenses	-
growth gross profit	1.92
growth gross profit ratio	1.85

COM:VIRBAC:CORPORATE

Virbac

Last Close

318.00

21/11 16:35

Market Cap

2.89B

Beta: -

Volume Today

2.03K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	1.35B
ebitda ratio	1
eps	-
eps diluted	-
operating expenses	-
operating income	1.35B
operating income ratio	1

accounts receivables	-
capital expenditure	-
cash at beginning of period	191.51M
cash at end of period	191.51M
inventory	-
working capital ttm	332.94M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-